2-Amino-4-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-1,3-thiazole-5-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Amino-4-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-1,3-thiazole-5-carbonitrile
• 英文别名: 2-amino-4-[2-(3,5-dimethylanilino)pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile
• 化学式: C₁₆H₁₄N₆S
• 分子量: 322.4
• InChiKey: HQSDNDCZRKBSFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-Amino-4-[2-(methylsulfonyl)pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile 、 2-Amino-4-[2-(methylsulfinyl)pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile 、 1-氨基-3,5-二甲苯 在 acetonitrile-water 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以to give 2-amino-4-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-1,3-thiazole-5-carbonitrile (4-4)的产率得到2-Amino-4-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-1,3-thiazole-5-carbonitrile
  参考文献：
  名称：

  Tyrosine kinase inhibitors

  摘要：

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号转导的化合物、包含这些化合物的组合物以及使用它们治疗哺乳动物中酪氨酸激酶依赖性疾病和病状的方法，例如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、炎症性疾病等。

  公开号：

  US20040181066A1

文献信息

• [EN] DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DE LA DIFFERENCIATION ET UTILISATIONS ASSOCIEES
  申请人：UNIV QUEENSLAND

  公开号：WO2005065686A1

  公开（公告）日：2005-07-21

  This invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signalling pathway, especially the FGF-1 or FGF-2 signalling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma and lipomatosis.

  该发明揭示了调节前脂肪细胞分化潜能和/或增殖的方法和药剂。更具体地，本发明揭示了调节成纤维细胞生长因子（FGF）信号通路的方法和药剂，特别是FGF-1或FGF-2信号通路，用于治疗或预防与脂肪相关的疾病，包括但不限于肥胖、脂肪瘤和脂肪增生。
• Differentiation modulating agents and uses therefor
  申请人：Prins Bernhard Johannes

  公开号：US20050282733A1

  公开（公告）日：2005-12-22

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
  申请人：Prins Johannes Bernhard

  公开号：US20120059047A1

  公开（公告）日：2012-03-08

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2003011838A1

  公开（公告）日：2003-02-13

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.